xMedica

NCT06932263ClinicalTrials.gov

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Fase 2540 partecipanti ricercati221 centri21 paesi

Categorie

Apparato respiratorio75%Immunologia e reumatologia25%

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered after enrolment began (about 22 days after the recorded start)First posted 2025-04-17; recorded start 2025-03-26
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 221 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 540 participants (target), run at 221 sites, across 21 countries.

How this score is built
  • Enrolment27/40

    540 participants (target)

  • Site count25/25

    221 sites

  • Country count15/15

    21 countries

  • Planned duration8/10

    Planned over about 36 months

  • Sponsor scale10/10

    AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Patologie

  • Asthma

Idoneità

SessoTutti
Età18 Years – 75 Years
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: 1. Provision of signed and dated written informed consent prior to any study-specific procedures. 2. Adults aged 18-75, inclusive when signing the informed consent. 3. Documented physician-diagnosis of asthma for at least 12 months. 4. Treated with medium or high dose ICS in combination with LABA. 5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 . 6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal. 7. Documented exacerbation history in the last 12 months and biomarker requirements of: 1. 2 severe exacerbations OR 2. 1 severe exacerbation and: (i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb 8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary. 9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test. 10. Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: 1. Completed treatment for respiratory infection with antibiotics in the 4 weeks prior to Visit 1. 2. Clinically significant pulmonary disease other than asthma . 3. Current smokers, former smokers with \>10 pack-years history. 4. Clinically significant aortic stenosis or pulmonary arterial hypertension. 5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immune complex disease. 6. Unstable cardiovascular disorders.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Tipo di studioInterventistico
FaseFase 2
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento540 partecipanti ricercati

Sponsor e collaboratori

  • AstraZeneca Sponsor

Bracci e interventi

  • Tozorakimab Dose 1EXPERIMENTAL

    Dosing subcutaneously tozorakimab Dose 1

  • Tozorakimab Dose 2EXPERIMENTAL

    Dosing subcutaneously tozorakimab Dose 2 and placebo

  • PlaceboPLACEBO_COMPARATOR

    Dosing subcutaneously with equivalent volume to tozorakimab

Interventi

  • Farmaco Placebo

    Placebo will be administered subcutaneously.

  • Farmaco Tozorakimab

    The drug will be administered subcutaneously.

Esiti misurati

  1. Esito primario

    Annualised rate of severe asthma exacerbations

    The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and ≥ 1 severe exacerbation within 12 months prior to screening.

    Orizzonte temporale Over 26 to 52 weeks

  2. Esito secondario

    Annualised rate of severe asthma exacerbations

    The rate ratio of severe asthma exacerbations will be assessed in the participants with uncontrolled moderate-to-severe asthma and baseline eosinophils \< 300 cells/µL and history of ≥2 severe exacerbations within 12 months prior to screening.

    Orizzonte temporale Over 26 to 52 weeks

  3. Esito secondario

    Time to first severe asthma exacerbation

    To evaluate the effect of two dose levels of tozorakimab compared to placebo on time to first severe asthma exacerbations.

    Orizzonte temporale Over 26 to 52 weeks

  4. Esito secondario

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1)

    Difference in mean change from baseline between tozorakimab and placebo.

    Orizzonte temporale Over weeks 20 to 26

  5. Esito secondario

    Change from baseline in post-bronchodilator FEV1

    Difference in mean change from baseline between tozorakimab and placebo.

    Orizzonte temporale At week 26

  6. Esito secondario

    Change from baseline in the Asthma Control Questionnaire 6 (ACQ-6)

    Difference in mean change from baseline between tozorakimab and placebo. The ACQ-6 has 6 questions (regarding asthma symptoms and rescue bronchodilator use). Answering the questions results in a score out of 6. A Score of 0 indicates complete control and 6 reflects severely uncontrolled disease.

    Orizzonte temporale At week 26

  7. Esito secondario

    Change from baseline in the Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ12+)

    Difference in mean change from baseline between tozorakimab and placebo. The AQLQ12+ includes 32 questions grouped into four domains: symptoms; activity limitations; emotional function; and, environmental stimuli. Each question is scored on a seven-point Likert scale, which ranges from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean of all questions, and the four domain scores are the means of the scores for the questions in the respective domains.

    Orizzonte temporale At week 26

  8. Esito secondario

    Trough serum concentrations of tozorakimab

    Pharmacokinetics: concentrations of tozorakimab in trough serum.

    Orizzonte temporale Over 52 weeks

  9. Esito secondario

    Anti-drug antibody incidence

    Immunogenicity: Number of Participants With Positive Antibodies to tozorakimab

    Orizzonte temporale Over 52 weeks

Date

Data di inizio26 marzo 2025 (effettiva)
Conclusione primaria7 giugno 2027 (stimata)
Conclusione28 febbraio 2028 (stimata)
Prima pubblicazione17 aprile 2025 (effettiva)
Ultimo aggiornamento20 luglio 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaluglio 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

150 centri stanno reclutando

Argentina

StrutturaCittàStato o regioneStato
Research SiteCABAIn reclutamento
Research SiteCiudad de Buenos AiresRitirato
Research SiteCiudad de Buenos AiresIn reclutamento
Research SiteLa PlataIn reclutamento
Research SiteMendozaIn reclutamento
Research SiteRosarioIn reclutamento
Research SiteSan Miguel de TucumánIn reclutamento

Brazil

StrutturaCittàStato o regioneStato
Research SiteCaxias do SulRitirato
Research SiteCriciúmaIn reclutamento
Research SitePorto AlegreIn reclutamento
Research SitePorto AlegreIn reclutamento
Research SiteSalvadorRitirato
Research SiteSanto AndréRitirato
Research SiteSorocabaIn reclutamento
Research SiteSão José do Rio PretoIn reclutamento
Research SiteSão PauloIn reclutamento
Research SiteSão PauloIn reclutamento

Chile

StrutturaCittàStato o regioneStato
Research SiteCuricóAttivo, non in reclutamento
Research SiteQuillotaAttivo, non in reclutamento
Research SiteSantiagoAttivo, non in reclutamento
Research SiteSantiagoAttivo, non in reclutamento
Research SiteSantiagoAttivo, non in reclutamento
Research SiteTemucoAttivo, non in reclutamento
Research SiteViña del MarAttivo, non in reclutamento

China

StrutturaCittàStato o regioneStato
Research SiteBaotouIn reclutamento
Research SiteChangchunIn reclutamento
Research SiteChengduIn reclutamento
Research SiteChongqingIn reclutamento
Research SiteGuangzhouIn reclutamento
Research SiteHaikouIn reclutamento
Research SiteHefeiIn reclutamento
Research SiteHohhotIn reclutamento
Research SiteHuizhouIn reclutamento
Research SiteQingdaoIn reclutamento
Research SiteShanghaiIn reclutamento
Research SiteShanghaiIn reclutamento
Research SiteShanghaiIn reclutamento
Research SiteShenzhenIn reclutamento
Research SiteWenzhouIn reclutamento
Research SiteXuzhouIn reclutamento

France

StrutturaCittàStato o regioneStato
Research SiteBrestIn reclutamento
Research SiteCréteilIn reclutamento
Research SiteLyonIn reclutamento
Research SiteMarseilleIn reclutamento
Research SitePessacIn reclutamento
Research SiteStrasbourgIn reclutamento
Research SiteSuresnesIn reclutamento

Greece

StrutturaCittàStato o regioneStato
Research SiteAthensIn reclutamento
Research SiteAthensIn reclutamento
Research SiteIoanninaRitirato

Nella scheda del registro sono indicati altri 171 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06932263